A HIF-2 antagonist, belzutifan, was recently approved as a treatment option as it showed promising results in case of VHL mutated and clear cell renal carcinoma, and is currently being evaluated regarding PPGL treatment [118]. The gene discussed is VHL; the disease is clear cell renal carcinoma.